Literature DB >> 6893053

Determination of nalidixic acid and its two major metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography.

G Cuisinaud, N Ferry, M Seccia, N Bernard, J Sassard.   

Abstract

This paper describes a precise and sensitive method for analysis of nalidixic acid and its two major metabolites in plasma and urine following the oral administration of a therapeutic dose in humans. After addition of an internal standard (oxolinic acid), 1-ml samples of plasma or urine are extracted at acidic pH with chloroform. The extracts are purified by re-extraction with sodium hydroxide solution and then chloroform. The final extracts are evaporated to dryness, reconstituted in mobile phase and injected into a high-performance liquid chromatograph equipped with RP-8 column and UV detector operating at 254 nm. The limit of sensitivity of the method is lower than 0.5 micrograms/ml of plasma or urine for each compound. The applicability of the method to pharmacokinetic studies of nalidixic acid in humans is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6893053     DOI: 10.1016/s0378-4347(00)81142-1

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.

Authors:  N Ferry; N Bernard; N Pozet; E Gardes; M Bruguier; G Cuisinaud; J Sassard
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

2.  Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.

Authors:  J G Christenson; K K Chan; R Cleeland; B Dix-Holzknecht; H H Farrish; I H Patel; A Specian
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys.

Authors:  L F McCoy; B P Crawmer; D P Benziger
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

4.  Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans.

Authors:  T B Vree; M van den Biggelaar-Martea; E W van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-06-18

5.  Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation.

Authors:  T B Vree; W J Wijnands; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1988-10-14

6.  Pharmacokinetics of chlormezanone in elderly patients.

Authors:  N Bernard; J P Fauvel; N Pozet; N Ferry; G Cuisinaud; P Haond; P Chapuy; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Nalidixic acid kinetics in renal insufficiency.

Authors:  G Cuisinaud; N Ferry; N Pozet; P Y Zech; J Sassard
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

8.  Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions.

Authors:  Boubakar Ba; Karen Gaudin; Amélie Désiré; Thida Phoeung; Marie-Hélène Langlois; Charan R Behl; Joel Unowsky; Indravadan H Patel; A Waseem Malick; Melba Gomes; Nicholas White; Tina Kauss
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.